$AMGN

As Fed hike looms, AI strategy’s mid-cap picks draw attention with 580% gain

U.S. 10-year Treasury yields hit 5%, highest since 2007, ahead of Fed decision with 90% chance of a 25-basis-point hike. Investing.com's Mid-Cap Movers strategy gained 580.7% since 2013, outperforming S&P MidCap 400. Top performers include Commvault (CVLT, +8.5%), Insight Enterprises (NSIT, +5.0%), and Wingstop (WING, +4.7%). Lennox International (LII) downgraded to Hold, Amgen (AMGN) FDA approval for Imdelltra.

Original reporting
Published Sep 15, 2026, 7:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 7:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$AMGN
Bullish
medium confidence
Mentioned
$AMGN · $LII
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AMGNBullishMed
01

Why it matters

The piece primarily serves as a strategy update; only Amgen’s FDA approval and Lennox’s downgrade constitute fresh, actionable information.

02

Market read

While the strategy’s performance is notable, the immediate trading relevance stems from the Amgen regulatory win and Lennox downgrade.

03

What to watch

Amgen's pipeline depth and upcoming data releases could drive longer‑term momentum beyond the single approval.

Relevance 7/10Novelty 7/10Timing: FDA approval announced September 14; downgrade issued September 14

Background

The article reviews Investing.com’s Mid‑Cap Movers strategy performance ahead of the Fed decision, highlighting a few individual holdings with recent news.

Company-level read

Ticker impact

$AMGNBullishMedium confidence
Context

FDA approved reduced monitoring time for Amgen's lung‑cancer drug Imdelltra, a fresh regulatory win.

Expected impact

Potential short‑term upside of 2‑4% on news day.

Evidence & confidence

FDA clearance removes a barrier and improves drug uptake, but broader stock trend remains weak.

$LIIBearishMedium confidence
Context

Deutsche Bank downgraded Lennox International to Hold with a new $444 price target.

Expected impact

Possible 1‑2% decline as investors reassess valuation.

Evidence & confidence

Analyst downgrade signals weaker outlook; price target remains above current price, limiting downside.

Market effects

Healthcare sector may see modest uplift from Amgen's approval, while industrials could face pressure from Lennox downgrade.

U.S. equities affected; no specific regional spillover.

Limited to investors tracking US healthcare and industrial stocks.

Counterpoint

Amgen's broader stock weakness may outweigh the approval benefit; investors could stay cautious.

Key entities

  • Amgen

    Biopharma firm receiving FDA clearance for Imdelltra monitoring change.

  • Lennox International

    Industrial HVAC maker downgraded by Deutsche Bank.

Related articles

$AMGNMed

Truist raises Amgen stock price target to $380 on pipeline growth

Truist Securities raised its price target for Amgen (AMGN) to $380, citing pipeline growth and revenue projections above consensus. The stock trades at $409.77, with a Fair Value estimate of $447.80. Amgen's Q3 2026 revenue is projected at $10.23B, with non-GAAP EPS of $5.90. Recent trial data for dazodalibep showed positive results, leading to varied analyst price targets.

$AMGNHighAI 9/10

Amgen’s ‘Imdelltra’ breaks ‘1-year survival barrier in SCLC – “i didn’t know it would be this good”

Amgen's Imdelltra (tarlatamab) showed significant results in a Phase 3 trial for small cell lung cancer (SCLC), extending median overall survival to 13.6 months, a 5.3-month improvement over chemotherapy. The trial, involving 509 patients, demonstrated a 40% reduction in death risk. Imdelltra is already approved in Korea for extensive-stage SCLC and has expanded indications.

$AMGNMedAI 9/10

Phase 3 Trial Shows Adding Imdelltra to First-Line Treatment Helps Patients With SCLC Live Longer

Amgen's phase 3 trial (DeLLphi-305) showed that adding Imdelltra (tarlatamab) to Imfinzi (durvalumab) as maintenance therapy improved overall and progression-free survival for extensive-stage small cell lung cancer (ES-SCLC) patients compared to Imfinzi alone. The trial enrolled 563 patients, and no new safety concerns were identified. Full results are pending. Imdelltra is not yet approved for this use.